You are here: Industry Insights > Market News > Brazilian Clinics plans deal with Bharat Biotech for five million doses of Covaxin

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Sulopenem CAS:120788-07-0

Sulopenem etzadroxil CAS:1000296-70-7

Pimobendan CAS:74150-27-9

ERDAFITINIB CAS:1346242-81-6

lenvatinib Mesylate CAS:857890-39-2

Dacomitinib

Brazilian Clinics plans deal with Bharat Biotech for five million doses of Covaxin

expresspharmaJanuary 05, 2021

Tag: ABCVAC , Covaxin , COVID-19 vaccine

Favorites

The Brazilian Association of Vaccine Clinics (ABCVAC) has informed through its website that it has signed MoU with Bharat Biotech to acquire around five million doses of Covaxin. However, the final say about the deal would rest with Anvisa, Brazil’s health regulator.

News agency AFP reports that a team from ABCVAC will travel to India for further discussions with Bharat Biotech.

ABCVAC said that this planned deal with Bharat Biotech is a step to ensure that Brazilians using the have access to COVID-19 vaccines through the private healthcare system.

Previous:Angelini Pharma acquires Arvelle Therapeutics for $960 million

Next:Drug activist group AIDAN raises concerns over EUA for COVAXIN

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Brazilian Clinics plans deal with Bharat Biotech for five million doses of Covaxin | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

Brazilian Clinics plans deal with Bharat Biotech for five million doses of Covaxin

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

Brazilian Clinics plans deal with Bharat Biotech for five million doses of Covaxin

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>